News FDA approves first generics of anticoagulant Xarelto The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.
News Bayer reveals phase 3 data for improved MRI contrast agent Bayer is close to filing a new MRI contrast agent that can reduce levels of gadolinium, which can have health and environmental consequences.
News Boehringer eyes third quarter FDA verdict for oral HER2 drug Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
News BridgeBio gets EU nod for ATTR cardiomyopathy drug BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.
News Bayer files finerenone in EU for heart failure Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?
News Bayer gains ground in two-fronted Parkinson's offensive Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
